Globe Newswire
Globe Newswire
More Globe Newswire
View Older Stories View Newer Stories-
Kura Oncology to Present Updated Data from KOMET-007 Combination Trial of Ziftomenib at ASH Annual Meeting
-
AQUALAB Launches SKALA Dry
-
METAGENOMI (NASDAQ: MGX) INVESTOR ALERT: Berger Montague Advises Investors to Inquire About a Securities Fraud Class Action
-
Umoja Biopharma Announces Oral and Poster Presentations at the 66th American Society of Hematology Annual Meeting
-
Agios to Present New Data on Mitapivat and Tebapivat in Rare Blood Disorders at 66th ASH Annual Meeting and Exposition
-
Century Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates
-
Honouring Veterans Through Second Careers During Veterans' Week
-
SAGA Metals Corp. Completes Second & Final Tranche of IPO Prospectus Offering
-
CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results
-
Turnstone Biologics Presents Preclinical Data Highlighting Potential for Selected Tumor-Infiltrating Lymphocyte (TIL) Therapy in Solid Tumors at the 2024 Society for Immunotherapy of Cancer (SITC) Ann
-
Nouscom’s Off-the-Shelf Neoantigen Immunotherapy, NOUS-209, Continues to Elicit Potent and Durable Immune Responses in Lynch Syndrome Carriers Highlighting its Potential to ‘Intercept’ Cancer
-
Candel Therapeutics to Present Preclinical Data at SITC Annual Meeting Showing Promise for CAN-3110 in Melanoma, Signaling Potential Indication Expansion Beyond Recurrent High-Grade Glioma
-
Revolution Medicines to Participate in Upcoming Investor Conferences
-
Innovative Food Holdings, Inc. Announces Q3 2024 Earnings Call
-
UFP Technologies Announces Record Q3 2024 Results
-
Free Gold IRA Kit Now Available For Download
-
Nomad The Label US Announces Launch of Luxurious Linen Clothing Collection
-
MKS Instruments Declares Quarterly Cash Dividend
-
Cogent Biosciences Announces Bezuclastinib Presentations at the 66th Annual American Society of Hematology (ASH) Meeting
-
Tessera Therapeutics to Present New Preclinical Data From In Vivo Programs for Sickle Cell Disease and T-Cell Therapies at the 66th American Society of Hematology Annual Meeting
-
Nurix Therapeutics Announces Presentations at the 66th American Society of Hematology (ASH) Annual Meeting
-
Capricor Therapeutics to Present Third Quarter 2024 Financial Results and Recent Corporate Update on November 13
-
America’s Car-Mart, Inc. Schedules Second Quarter Fiscal Year 2025 Results and Conference Call
-
Keros Therapeutics to Present at the 66th American Society of Hematology Annual Meeting and Exposition
-
Tenstorrent Expands Deployment of Arteris’ Network-on-Chip IP to Next-Generation of Chiplet-Based AI Solutions
-
Electromagnetic Survey Identifies Multiple Strong Targets Coincident with Elevated Gold and Silver at Star River
-
MKS Instruments Announces Appointment of Wissam Jabre to its Board of Directors
-
Outpace Bio to present new data on programmed CAR T cell candidate OPB-101 at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting
-
Ichnos Glenmark Innovation (IGI) Announces First Presentation of Data from Phase 1 Study of the Trispecific ISB 2001 in Relapsed/Refractory Multiple Myeloma (r/rMM) at Upcoming ASH Annual Meeting
-
SectorNet and Carahsoft Partner to Deliver Secure Collaboration Solutions to the Public Sector
-
IN8bio Announces Upcoming Presentation at the 2024 American Society of Hematology (ASH) Annual Meeting
-
Ivans Index October 2024 Results Released
-
Affimed Announces Acceptance of Three Abstracts at the 2024 ASH Annual Meeting Including an Oral Presentation Underscoring Advancing Clinical Pipeline in Leukemia and Lymphoma
-
Auron to Present New Preclinical Data for AUTX-703 at 2024 ASH Meeting
-
Latest WSO2 API Management Products Help Enterprises to Manage AI APIs, Maximize Developer Productivity, and Future-Proof Their Deployments
-
FortisBC Inc. joins General Fusion's Market Development Advisory Committee to examine potential for fusion energy deployment
-
Ken Marks Joins Cynomi as Chief Revenue Officer
-
Seanergy Maritime Reports Third Quarter and Nine Months Financial Results for the Periods Ended September 30, 2024
-
Global-e to Announce Financial Results for the Third Quarter 2024 on November 20, 2024
-
Bybit Powered by SATOS Introduces Exclusive Referral Bonuses for Dutch Users
-
Blink to establish a £100 million Special Purpose Vehicle to Drive Electric Vehicle Charger Investments, Engaging Axxeltrova Capital as First Funding Partner
-
Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2024 in One Oral Presentation and Three Poster Presentations
-
PrognomiQ Announces $34 Million Series D Financing to Advance Development of Early Detection Test for Lung Cancer with Multi-omics Platform
-
NeurAxis to Host Third Quarter 2024 Results and Business Update Call on Tuesday, November 12, 2024
-
FortisBC Inc. joins General Fusion's Market Development Advisory Committee to examine potential for fusion energy deployment
-
Kronos Bio to Present Data at the ASH Annual Meeting from p300 KAT Inhibition Program in Multiple Myeloma
-
Disc Medicine Announces Multiple Presentations Across Portfolio at the 66th American Society of Hematology (ASH) Annual Meeting
-
Cartesian Therapeutics Announces Presentation at the Upcoming 66th ASH Annual Meeting
-
C4 Therapeutics to Present Data from the Ongoing Phase 1/2 Trial of Cemsidomide in Multiple Myeloma and Non-Hodgkin’s Lymphoma at the American Society of Hematology (ASH) Annual Meeting
-
Beam Therapeutics to Present Data Across Hematology Franchise, Including First Clinical Data for BEAM-101 in Sickle Cell Disease and ESCAPE Non-human Primate Data, at American Society of Hematology (A
